IN THE CLAIMS

The status of each claim in the present application is listed below.

Please amend the claims as follows:

Claim 1 (Currently Amended): An active substance combination, comprising: ~~characterized in that it comprises:~~

(A) at least one compound with neuropeptide Y (NPY) -receptor affinity, and

(B) at least one compound with 5-HT_6 receptor affinity.

Claim 2 (Currently Amended): The combination according to claim 1, wherein ~~characterized in that~~ as component (A) at least one compound with neuropeptide Y5 (NPY5) -receptor affinity is present.

Claim 3 (Currently Amended): The combination according to claim 1 or 2, wherein ~~characterized in that~~ as component (A) at least one compound is present, which is a ~~selected from the group consisting of the~~ 1,4-disubstituted piperidine compound ~~compounds~~ of general formula (Ia)



(Ia)

wherein R^{1a}, R^{2a}, R^{3a}, R^{4a} are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro, cyano, $-OR^{12a}$, $-O-(C=O)R^{13a}$,$-(C=O)-OR^{13a}$, $-SR^{14a}$, $-SOR^{14a}$, $-SO_2R^{14a}$, $-NH-SO_2R^{14a}$, $-SO_2NH_2$ and $-NR^{15a}R^{16a}$ moiety,

R^{5a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical,

R^{6a}, R^{7a}, R^{8a}, R^{9a} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano and a $COOR^{17a}$ moiety,

A^a represents a bridge member $-CHR^{18a}-$ or $-CHR^{18a}-CH_2-$,

B^a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, a $COOR^{19a}$-moiety, a $-(C=O)R^{20a}$-moiety, or a $-CH_2OR^{23a}$-moiety,

R^{10a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{11a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, or an optionally at least mono substituted aryl- or heteroaryl radical, which may

be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono- substituted mono- or polycyclic ringsystem, or

R^{10a} and R^{11a} together with the bridging nitrogen atom form an optionally at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring that may contain at least one further heteroatom as a ring member and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem,

R^{12a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{13a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono- substituted mono- or polycyclic ring-system,

R^{14a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono- substituted mono- or polycyclic ring-system,

R^{15a} and R^{16a} each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

or R^{15a} and R^{16a} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

R^{17a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical,

which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{18a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{19a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{20a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or a $NR^{21a}R^{22a}$-moiety,

R^{21a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{22a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at

least mono-substituted cycloaliphatic radical, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{23a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, which may comprise at least one heteroatom as a chain member, or a- $(C=O)R^{13a}$-moiety,

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, ~~preferably enantiomers or diastereomers,~~ in any mixing ratio, or salts~~, preferably physiologically acceptable salts thereof, or corresponding solvates~~.

Claim 4 (Currently Amended): The combination according to claim 1 or 2 ~~any one of the claims 1 to 3~~, wherein ~~characterized in that~~ as component (B) at least one compound [[ist]] is present, which is a ~~selected from the group consisting of the~~ benzoxazinone-derived sulfonamide compound ~~compounds~~ of general formula (Ib)



(Ib)

wherein

R^{1b}, R^{2b}, R^{3b}, R^{4b} are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro, cyano, $-OR^{10b}$, $-O(C=O)R^{11b}$, $-(C=O)OR^{11b}$, $-SR^{12b}$, $-SOR^{12b}$, $-SO_2R^{12b}$, $-NH-SO_2R^{12b}$, $-SO_2NH_2$ and a $-NR^{13b}R^{14b}$ moiety,

R^{5b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical,

R^{6b}, R^{7b}, R^{8b}, R^{9b} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a $COOR^{15b}$ moiety,

W^b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

an optionally at least mono-substituted aryl or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene or alkenylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

a $NR^{16b}R^{17b}$-moicty or

a COR^{18b}-moiety,

R^{10b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono-

or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{11b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono- substituted mono- or polycyclic ring-system,

R^{12b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{13b} and R^{14b} each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded

via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

or R^{13b} and R^{14b} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

R^{15b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{16b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{17b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, and

R^{18} represents an optionally at least mono-substituted aryl radical optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, ~~or a solvate,~~ respectively, and. compounds derived from sulfonamide of general formula (Ic),



(Ic)

wherein R^{1c} represents hydrogen, an optionally at least mono-substituted, linear or branched alkyl radical, an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted benzyl radical,

R^{2c} represents a $-NR^{4c}R^{5c}$ moiety or a saturated or unsaturated, optionally at least mono-substituted, optionally at-least one heteroatom as ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing mono- or bicyclic cycloaliphatic ringsystem,

R^{3c} represents hydrogen or an optionally at least mono-substituted, linear or branched alkyl radical,

R^{4c} and R^{5c}, identical or different, represent hydrogen or an optionally at least mono-substituted, linear or branched alkyl radical, or

R^{4c} and R^{5c} together with the bridging nitrogen atom form an optionally at least mono-substituted, saturated or unsaturated heterocyclic ring, which may contain at least one further heteroatom as a ring member and/or may be condensed with a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing mono- or bicyclic cycloaliphatic ringsystem,

A^c represents an optionally at least mono-substituted mono- or polycyclic aromatic ringsystem, which may be bonded via an optionally at least mono-substituted alkylene-, an optionally at least mono-substituted alkenylene-or an optionally at least mono-substituted alkynylene group and/or may contain at least one heteroatom as a ring member in one or more of its rings,

nc represents 0,1, 2,3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding physiologically acceptable salt ~~or a corresponding solvate~~, and compounds of general formula (Id)



(Id)

R^{1d} represents a $-NR^{8d}R^{9d}$ radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R^{2d}, R^{3d}, R^{5d}, R^{6d} and R^{7d}, identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or an optionally at least mono-substituted heteroaryl radical,

R^{4d} is hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R^{8d} and R^{9d}, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or

R^{8d} and R^{9d} together with bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,

A^d represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

and

nd is 0,1, 2,3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, ~~or a corresponding solvate thereof~~,

and compounds derived from sulfonamide of general formula (Ie)



(Ie)

wherein

~~wherein~~

R^{1e} represents an $-NR^{8e}R^{9e}$ radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may optionally contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,

R^{2e}, R^{3e}, R^{4e}, R^{6e} and R^{7e}, identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical or an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted heteroaryl radical,

R^{5e} represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R^{8e} and R^{9e}, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or

R^{8c} and R^{9c} together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, mono- or bicyclic cycloaliphatic ring system which may optionally contain at least one heteroatom as a ring member,

A^c represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

and

ne is 0, 1,2, 3 or 4;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, at any mixture ratio, or a corresponding, physiologically acceptable salt, ~~or a corresponding solvate~~, and compounds derived from sulfonamide of general formula (If)



(If)

wherein

R^{1f} represents a $-NR^{8f}R^{9f}$ radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R^{2f}, R^{3f}, R^{4f}, R^{5f} and R^{7f}, identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted heteroaryl radical,

R^{6f} represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R^{8f} and R^{9f}, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or

R^{8f} and R^{9f}, together with the bridging nitrogen atom, form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one further heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

A^f represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings

and

nf is 0, 1,2, 3 or 4;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, at any mixture ratio, or a corresponding, physiologically acceptable salt, ~~or a corresponding solvate~~, and compounds derived from sulfonamide of general formula (Ig)



(Ig)

wherein

R^{1g} is a $-NR^{8g}R^{9g}$ radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may optionally contain at least one heteroatom as a ring member and which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring ~~systemwhich~~ system which may optionally contain at least one heteroatom as a ring member,

R^{2g}, R^{3g}, R^{4g}, R^{5g} and R^{6g}, identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted heteroaryl radical,

R^{7g} represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R^{8g} and R^{9g}, identical or different, represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or

R^{8g} and R^{9g} together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,

A^g represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

ng is 0,1, 2,3 or 4;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, at any mixture ratio, or a corresponding, physiologically acceptable salt, ~~or a corresponding solvate~~ and compounds derived from sulfonamide of general formula (Ih)



(Ih)

wherein

R^{1h} represents a $-NR^{7h}R^{8h}$ radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R^{2h}, R^{3h}, R^{4h}, R^{5h} and R^{6h}, identical or different, each represent hydrogen, halogen, cyano, nitro, a linear or branched alkyl radical, a linear or branched alkenyl radical, a linear or branched alkenyl radical, a linear or branched alkoxy radical, a linear or branched alkylthio radical, hydroxy, trifluoromethyl, a cycloalkyl radical, a cycloalkenyl radical, an alkylcarbonyl radical, a phenylcarbonyl or a $-NR^{9h}R^{10h}$ group,

R^{7h} and R^{8h}, identical or different, each represent hydrogen or a saturated or unsaturated, optionally at least mono-substituted linear or branched aliphatic radical,

or

R^{7h} and R^{8h}, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring

member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R^{9h} and R^{10h}, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or

R^{9h} and R^{10h}, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

A^h and B^h, identical or different, each represent a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical

or

A^h and B^h, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring,

and

nh is 0, 1,2, 3 or 4

optionally in the form of one of their stereoisomers, ~~preferably enantiomers or diastereomers,~~ their racemate or in the form of a mixture of at least two of their stereoisomers, ~~preferably enantiomers or diastereomers,~~ at any mixture ratio, or a corresponding physiologically acceptable salt ~~or a corresponding solvate~~.

Claim 5 (Currently Amended): The combination according to claim 1 or 2 ~~any one of the claims 1 to 4~~, wherein ~~characterized in that~~ it comprises 1-99% by weight of component

(A) and 99-1 % by weight of component (B)~~, more preferably 10-80% by weight of component (A) and 90-20% by weight of component (B)~~, in each case referring to the total weight of both components (A) and (B).

Claim 6 (Currently Amended): A pharmaceutical composition ~~medicament~~ comprising an active substance combination ~~acording~~ according to claim 1 or 2 ~~any one of the claims 1 to 5~~ and optionally one or more pharmacologically acceptable adjuvants.

Claim 7 (Currently Amended): A pharmaceutical composition ~~medicament~~ according to claim 6, for simultaneous neuropeptide Y- and ~~Y and~~ 5-HT_6-receptor regulation, for regulation of appetite, for maintenance, increase or reduction of body weight, for prophylaxis and/or treatment of disorders related to food ingestion, preferably for prophylaxis and/or treatment of obesity, anorexia, cachexia, bulimia, diabetes, preferably type II diabetes (non-insulin-dependent diabetes mellitus), or for prophylaxis and/or treatment of gastrointestinal tract disorders, preferably of the irritable bowel syndrome, for prophylaxis and/or treatment of Peripheral Nervous System Disorders, Central Nervous System Disorders, arthritis, epilepsy, anxiety, panic, depression, cognitive disorders, memory disorders, cardiovascular diseases, senile dementia processes, such as Alzheimer's, Parkinson's and/or Huntington's Disease, schizophrenia, psychosis, infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder), pain, hypertensive syndrome, inflammatoric diseases, immunologic diseases or for improvement of cognition.

Claims 8-33: (Canceled).

Claim 34 (Currently Amended): A pharmaceutical formulation, which ~~characterized in that it~~ comprises an active substance combination according to any one of claims 1 or 2 [[5]] and optionally one or more pharmacologically acceptable adjuvants.

Claim 35 (Currently Amended): The pharmaceutical formulation according to claim 34, which ~~characterized in that it~~ is present in solid pharmaceutical forms such as tablets, tablets, chewing tablets, chewing gums, dragees, capsules, suppositories, powder preparations, transdermal therapeutic systems, transmucosal therapeutic systems, or in liquid and semi-liquid pharmaceutical forms such as drops or such as juice, ~~sirup~~ syrup, solution, emulsion, suspension, preferably in form of tablets, capsules, drops or solution.

Claim 36 (Currently Amended): The pharmaceutical formulation according to claim 34, which ~~characterized in that it~~ is present in form of [[of]] multiple particles, preferably microtablets, microcapsules, microspheroids, granules, crystals or pellets, optionally compacted in a tablet, filled in a capsule or suspended in a suitable liquid.

Claim 37 (Currently Amended): The pharmaceutical formulation according to one or more of claims 34-36, which ~~characterized in that it~~ is for oral, intravenous, intramuscular, subcutaneous, intrathecal, epidural, buccal, sublingual, pulmonal, rectal, transdermal, nasal or intracerebroventricular application~~, preferably oral or intravenous~~.

Claim 38 (Currently Amended): The pharmaceutical formulation according to one or more of claims 34-36, wherein ~~characterized in that~~ at least one of the components of the active substance combination (A) or (B) is present at least partially in sustained-release form.

Claim 39 (Currently Amended): The pharmaceutical formulation according to claim 38, wherein ~~characterized in that~~ the medicament has at least one coating or at least one matrix comprising at least one material, which sustains active substance release.

Claim 40 (Currently Amended): The pharmaceutical formulation according to claim 39, wherein ~~characterized in that~~ the sustained-release material is based on optionally modified, water-insoluble, natural, semisynthetic or synthetic polymer, or a natural wax or fat or fatty alcohol or semisynthetic or synthetic fatty acid, or on a mixture of at least two of these afore mentioned components.

Claim 41 (Currently Amended): The pharmaceutical formulation according to claim 40, wherein ~~characterized in that~~ the water-insoluble polymer is based on an acrylic resin, which is preferably selected from the group of poly(meth)acrylates, poly(C_{1-4})dialkylamino(C_{1-4})alkyl (meth)acrylates and/or copolymers thereof or a mixture of at least two of the afore-mentioned polymers.

Claim 42 (Currently Amended): The pharmaceutical formulation according to claim 40, wherein ~~characterized in that~~ the water-insoluble polymers are cellulose derivatives, preferably alkyl cellulose and even more preferably ethyl cellulose, or cellulose esters.

Claim 43 (Currently Amended): The pharmaceutical formulation according to claim 40, wherein ~~characterized in that~~ the wax is carnauba wax, beeswax, glycerol monostearate, glycerol monobehenate, glycerol ditripalmitostearate, microcrystalline wax or a mixture of at least two of these components.

Claim 44 (Currently Amended): The pharmaceutical formulation according to one or more of claims 40-43, wherein ~~characterized in that~~ polymers have been used in combination with one or more plasticizers.

Claim 45 (Currently Amended): The pharmaceutical formulation according to one or more of claims 38-44, wherein ~~characterized in that~~ besides the sustained-release form, at least one of the active substance components (A) or (B) is present in a non-sustained-release form.

Claim 46 (New): A method of simultaneously regulating neuropeptide Y5- and 5-HT_6-receptor, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 47 (New): A method of regulating appetite, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 48 (New): A method of maintaining, increasing or reducing body weight, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 49 (New): A method for prophylaxis and/or treatment of disorders related to food ingestion, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 50 (New): A method for prophylaxis and/or treatment of obesity, anorexia, cachexia, bulimia, diabetes, preferably type II diabetes, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 51 (New): A method for prophylaxis and/or treatment of gastrointestinal tract disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 52 (New): A method for prophylaxis and/or treatment of the irritable bowel syndrome, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 53 (New): A method for prophylaxis and/or treatment of Peripheral Nervous System Disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 54 (New): A method for prophylaxis and/or treatment of Central Nervous System Disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 55 (New): A method for prophylaxis and/or treatment arthritis, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 56 (New): A method for prophylaxis and/or treatment of epilepsy, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 57 (New): A method for prophylaxis and/or treatment of anxiety, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 58 (New): A method for prophylaxis and/or treatment of panic, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 59 (New): A method for prophylaxis and/or treatment of depression comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 60 (New): A method for prophylaxis and/or treatment of bipolar disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 61 (New): A method for prophylaxis and/or treatment of cognitive disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 62 (New): A method for prophylaxis and/or treatment of memory disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 63 (New): A method for prophylaxis and/or treatment of cardiovascular diseases, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 64 (New): A method for prophylaxis and/or treatment of senile dementia processes, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 65 (New): A method for prophylaxis and/or treatment of neurodegenerative disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 66 (New): A method for prophylaxis and/or treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease or multiple sclerosis, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 67 (New): A method for prophylaxis and/or treatment of schizophrenia, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 68 (New): A method for prophylaxis and/or treatment of psychosis, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 69 (New): A method for prophylaxis and/or treatment of infantile hyperkinesia or attention deficit/hyperactivity disorder, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 70 (New): A method for prophylaxis and/or treatment of pain, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 71 (New): A method for prophylaxis and/or treatment of hypertensive syndrome, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 72 (New): A method for prophylaxis and/or treatment of inflammatoric diseases, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 73 (New): A method for prophylaxis and/or treatment of immunologic diseases, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 74 (New): A method for improving cognition, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.